CO2020000357A2 - Receptores de células t novedosos, e inmunoterapia usando los mismos - Google Patents
Receptores de células t novedosos, e inmunoterapia usando los mismosInfo
- Publication number
- CO2020000357A2 CO2020000357A2 CONC2020/0000357A CO2020000357A CO2020000357A2 CO 2020000357 A2 CO2020000357 A2 CO 2020000357A2 CO 2020000357 A CO2020000357 A CO 2020000357A CO 2020000357 A2 CO2020000357 A2 CO 2020000357A2
- Authority
- CO
- Colombia
- Prior art keywords
- antigen
- spink2
- recognizing constructs
- taa
- tcr
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title 1
- 101001077727 Homo sapiens Serine protease inhibitor Kazal-type 2 Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102100025419 Serine protease inhibitor Kazal-type 2 Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 229940119135 Serine peptidase inhibitor Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Abstract
La presente invención se refiere a constructos reconocedores de antígeno dirigidos contra antígenos asociados a tumores (TAA), en particular contra el TAA denominado inhibidor de serina peptidasa Kazal de tipo 2 (SPINK2). La invención proporciona, en concreto, mo-léculas novedosas basadas en un nuevo receptor de células T (TCR) que son selectivas y específicas hacia el antígeno de la invención que es expresado por tumores. El TCR de la invención, así como los fragmentos de unión con el antígeno SPINK2 y que derivan del mismo, están destinados al uso en el diagnóstico, el tratamiento y la prevención de enfer-medades tumorales que expresan el SPINK2. Además, se proporcionan ácidos nucleicos que codifican los constructos reconocedores del antígeno de la invención, los vectores que comprenden esos ácidos nucleicos, las células recombinantes que expresan los constructos reconocedores del antígeno, y las composiciones farmacéuticas que comprenden los com-puestos de la invención.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762527844P | 2017-06-30 | 2017-06-30 | |
DE102017114737.3A DE102017114737A1 (de) | 2017-06-30 | 2017-06-30 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
PCT/EP2018/067380 WO2019002444A1 (en) | 2017-06-30 | 2018-06-28 | NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020000357A2 true CO2020000357A2 (es) | 2020-01-31 |
Family
ID=64662173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0000357A CO2020000357A2 (es) | 2017-06-30 | 2020-01-14 | Receptores de células t novedosos, e inmunoterapia usando los mismos |
Country Status (20)
Country | Link |
---|---|
US (4) | US10590194B2 (es) |
EP (1) | EP3645573A1 (es) |
JP (1) | JP7235316B2 (es) |
KR (1) | KR20200023288A (es) |
CN (1) | CN110753705A (es) |
AR (1) | AR112604A1 (es) |
AU (1) | AU2018293322A1 (es) |
BR (1) | BR112019025323A2 (es) |
CA (1) | CA3067757A1 (es) |
CL (1) | CL2019003885A1 (es) |
CO (1) | CO2020000357A2 (es) |
CR (1) | CR20190594A (es) |
DE (1) | DE102017114737A1 (es) |
IL (1) | IL271751A (es) |
MA (1) | MA49503A (es) |
MX (1) | MX2019015742A (es) |
PE (1) | PE20200337A1 (es) |
SG (1) | SG11201911437VA (es) |
TW (1) | TWI727182B (es) |
WO (1) | WO2019002444A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20230343A1 (es) * | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | Peptidos que estimulan respuestas inmunitarias antitumorales |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
CN112442119B (zh) * | 2019-09-05 | 2023-02-24 | 香雪生命科学技术(广东)有限公司 | 一种识别ssx2的高亲和力t细胞受体 |
MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
US20220356252A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
WO2000006732A2 (en) * | 1998-07-31 | 2000-02-10 | Diagnostic Products Corporation | Polynucleotide encoding an autoantigen associated with endometriosis |
WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
GB0525999D0 (en) * | 2005-12-21 | 2006-02-01 | Ares Trading Sa | Novel members of the kazal family of serine protease inhibitors |
KR101669279B1 (ko) * | 2007-03-05 | 2016-10-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
EP3748001A1 (en) | 2012-08-08 | 2020-12-09 | Daiichi Sankyo Company, Limited | Peptide library and use thereof |
EP3572423B1 (en) * | 2013-07-15 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-human papillomavirus 16 e6 t cell receptors |
GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
US10066002B2 (en) * | 2014-11-05 | 2018-09-04 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
EP3156067A1 (en) * | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
GB201520597D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520567D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
-
2017
- 2017-06-30 DE DE102017114737.3A patent/DE102017114737A1/de active Pending
-
2018
- 2018-06-28 MA MA049503A patent/MA49503A/fr unknown
- 2018-06-28 AU AU2018293322A patent/AU2018293322A1/en active Pending
- 2018-06-28 CR CR20190594A patent/CR20190594A/es unknown
- 2018-06-28 CN CN201880033171.0A patent/CN110753705A/zh active Pending
- 2018-06-28 KR KR1020197036902A patent/KR20200023288A/ko not_active Application Discontinuation
- 2018-06-28 MX MX2019015742A patent/MX2019015742A/es unknown
- 2018-06-28 BR BR112019025323-8A patent/BR112019025323A2/pt unknown
- 2018-06-28 PE PE2019002620A patent/PE20200337A1/es unknown
- 2018-06-28 TW TW107122290A patent/TWI727182B/zh active
- 2018-06-28 WO PCT/EP2018/067380 patent/WO2019002444A1/en unknown
- 2018-06-28 SG SG11201911437VA patent/SG11201911437VA/en unknown
- 2018-06-28 CA CA3067757A patent/CA3067757A1/en active Pending
- 2018-06-28 EP EP18737546.4A patent/EP3645573A1/en active Pending
- 2018-06-28 JP JP2019569676A patent/JP7235316B2/ja active Active
- 2018-06-29 AR ARP180101832 patent/AR112604A1/es unknown
- 2018-06-29 US US16/023,731 patent/US10590194B2/en not_active Expired - Fee Related
-
2019
- 2019-05-03 US US16/403,269 patent/US10723796B2/en active Active
- 2019-12-27 CL CL2019003885A patent/CL2019003885A1/es unknown
- 2019-12-29 IL IL271751A patent/IL271751A/en unknown
-
2020
- 2020-01-03 US US16/733,845 patent/US11111294B2/en active Active
- 2020-01-14 CO CONC2020/0000357A patent/CO2020000357A2/es unknown
-
2021
- 2021-08-09 US US17/397,656 patent/US20210388079A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020529830A (ja) | 2020-10-15 |
BR112019025323A2 (pt) | 2020-06-23 |
CR20190594A (es) | 2020-03-02 |
US11111294B2 (en) | 2021-09-07 |
IL271751A (en) | 2020-02-27 |
EP3645573A1 (en) | 2020-05-06 |
WO2019002444A1 (en) | 2019-01-03 |
TWI727182B (zh) | 2021-05-11 |
US10723796B2 (en) | 2020-07-28 |
JP7235316B2 (ja) | 2023-03-08 |
AU2018293322A1 (en) | 2020-01-16 |
US20200140540A1 (en) | 2020-05-07 |
US10590194B2 (en) | 2020-03-17 |
DE102017114737A1 (de) | 2019-01-03 |
MA49503A (fr) | 2020-05-06 |
TW201904989A (zh) | 2019-02-01 |
US20210388079A1 (en) | 2021-12-16 |
SG11201911437VA (en) | 2020-01-30 |
PE20200337A1 (es) | 2020-02-14 |
WO2019002444A9 (en) | 2019-03-14 |
CL2019003885A1 (es) | 2020-05-29 |
CA3067757A1 (en) | 2019-01-03 |
KR20200023288A (ko) | 2020-03-04 |
CN110753705A (zh) | 2020-02-04 |
AR112604A1 (es) | 2019-11-20 |
US20190002556A1 (en) | 2019-01-03 |
MX2019015742A (es) | 2020-02-20 |
US20190256590A1 (en) | 2019-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020000357A2 (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
CO2019011688A2 (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame | |
CO2020006905A2 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos | |
CR20190095A (es) | Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos | |
CL2021002997A1 (es) | Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535) | |
DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
CR20190278A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
WO2018172533A3 (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
CL2017000311A1 (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
PE20171790A1 (es) | Anticuerpos anti-ceacam6 y sus usos | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
CL2019000366A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
PE20160716A1 (es) | Anticuerpo anti-tweakr y sus usos | |
EA202190243A1 (ru) | Применение химерных антигенных рецепторов к bcma | |
PE20210665A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
AR113834A1 (es) | Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos | |
AR109345A1 (es) | Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
CO2019002229A2 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
EA201992583A1 (ru) | Новые t-клеточные рецепторы и иммунотерапия с их применением | |
EA201992002A1 (ru) | Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением | |
EA201990488A1 (ru) | Новые t-клеточные рецепторы и иммунотерапия с их применением | |
EA201991151A1 (ru) | Новые т-клеточные рецепторы и иммунотерапия с их применением |